During the ongoing Covid-19 pandemic, the FDA has continued in its normal role of approving safe and effective drugs. But how do pharma companies go about bringing a new drug to market during the pandemic? Immunomedics’ chief commercial officer Brendan Delaney explains how his company has successfully facilitated the treatment of US patients with its first ever drug, Trodelvy, which was approved at the end of April. Immunomedics’ first approved is Trodelvy, an ADC indicated for heavily treated metastatic TNBC. Credit: Shutterstock.